

This checklist concerns the design and conduct of *in vivo* preclinical studies that are performed to establish the clinical utility of new treatments (“efficacy studies”). In particular, the checklist is aimed at helping researchers, reviewers, and others determine whether a given experiment or a group of experiments has addressed factors that threaten the reliability and clinical generalizability of study findings. Items below should be clearly reported in publications. Note: This checklist has not undergone a formal development and validation process, including evaluations of face, criterion, and content validity.

## Internal Validity

		Yes	No
<b>1a</b>	Were treatments allocated to animals using a randomized procedure?	<input type="checkbox"/>	<input type="checkbox"/>
<b>1b</b>	If “Yes”, describe the method used to generate the randomization sequence:		
<b>1c</b>	If non-randomized allocation was used, were groups balanced by another characteristic (e.g. sex, age, disease status)?	<input type="checkbox"/>	<input type="checkbox"/>
<b>2</b>	Was the handling of animals before and during the experiment uniform (e.g. same handlers, standardized animal training)?	<input type="checkbox"/>	<input type="checkbox"/>
<b>3</b>	Was the emergence of confounding physiological variables monitored and addressed (e.g. blood pressure, body temperature)?	<input type="checkbox"/>	<input type="checkbox"/>
<b>4</b>	If anesthesia or analgesia were used during the experiment, were potential confounding effects on outcomes addressed?	<input type="checkbox"/>	<input type="checkbox"/>
<b>5</b>	Were appropriate controls used in all <i>in vivo</i> experiments (e.g. positive, negative)?	<input type="checkbox"/>	<input type="checkbox"/>
<b>6</b>	Was treatment allocation concealed from the investigators during the experiment?	<input type="checkbox"/>	<input type="checkbox"/>
<b>7</b>	Were investigators blinded to treatment allocation during outcome assessment?	<input type="checkbox"/>	<input type="checkbox"/>
<b>8</b>	Has a dose-response treatment effect been demonstrated?	<input type="checkbox"/>	<input type="checkbox"/>
<b>9</b>	Were measures taken to ensure that outcome assessment techniques were consistent and reproducible (e.g. training of research personnel, performing assessments in same location)?	<input type="checkbox"/>	<input type="checkbox"/>
<b>10</b>	Has precision of the treatment effect been justified, and is choice of measure of dispersion justified?	<input type="checkbox"/>	<input type="checkbox"/>
<b>11</b>	Are the statistical tests appropriate, reported in detail, and sufficiently justified?	<input type="checkbox"/>	<input type="checkbox"/>
<b>12</b>	Has every animal been accounted for, from entry into experiment through treatment, outcome assessment, sacrifice and analysis?	<input type="checkbox"/>	<input type="checkbox"/>
<b>13a</b>	Has a power calculation been performed <i>a priori</i> to determine sample size?	<input type="checkbox"/>	<input type="checkbox"/>
<b>13b</b>	If “No,” how was the sample size chosen:		

## External Validity

		Yes	No
<b>14</b>	Have treatment effects been demonstrated in more than one model?	<input type="checkbox"/>	<input type="checkbox"/>
<b>15</b>	Have treatment effects been replicated by an independent research group?	<input type="checkbox"/>	<input type="checkbox"/>

## Construct Validity

		Yes	No
<b>16a</b>	Is the selected animal model the best available representation of human disease?	<input type="checkbox"/>	<input type="checkbox"/>
<b>16b</b>	If "Yes", on what basis?		
<b>17</b>	Did the experiment simulate the delivery of treatments that are co-administered in typical clinical settings?	<input type="checkbox"/>	<input type="checkbox"/>
<b>18</b>	Have comorbidities typical of clinical settings been simulated in the experiment?	<input type="checkbox"/>	<input type="checkbox"/>
<b>19</b>	Does the age of animals match the age of patients in relevant clinical settings?	<input type="checkbox"/>	<input type="checkbox"/>
<b>20a</b>	Were basic animal characteristics sufficiently defined at baseline (e.g. strain, sex, age, disease status)?	<input type="checkbox"/>	<input type="checkbox"/>
<b>20b</b>	Were predetermined inclusion and exclusion criteria used?	<input type="checkbox"/>	<input type="checkbox"/>
<b>21</b>	Has the timing of treatment administration been matched to the timing of administration anticipated in clinical settings?	<input type="checkbox"/>	<input type="checkbox"/>
<b>22</b>	Was appropriate delivery of treatment confirmed (e.g. to the appropriate organ system or compartment)?	<input type="checkbox"/>	<input type="checkbox"/>
<b>23</b>	Were confounders that might result from treatment addressed (e.g. effects of a drug on other systems, complications from treatment administration)?	<input type="checkbox"/>	<input type="checkbox"/>
<b>24</b>	Were the measures of disease response the best available representations of those used in clinical settings?	<input type="checkbox"/>	<input type="checkbox"/>
<b>25</b>	Have the outcome assessment techniques and criteria been validated and shown to be reproducible?	<input type="checkbox"/>	<input type="checkbox"/>
<b>26</b>	Have treatment effects been demonstrated using more than one measure of response?	<input type="checkbox"/>	<input type="checkbox"/>
<b>27</b>	Has treatment response been demonstrated at a mechanistic level?	<input type="checkbox"/>	<input type="checkbox"/>
<b>28</b>	Are there aspects of the experimental environment that could interfere with clinical generalization (e.g. stressors such as noise, housing)?	<input type="checkbox"/>	<input type="checkbox"/>

## Research Program

		Yes	No
<b>29</b>	Was study design standardized such that results can be compared with similar preclinical studies?	<input type="checkbox"/>	<input type="checkbox"/>